Ligand Pharmaceuticals Incorporated (LGND) Q2 2011 Earnings Results

Ligand Pharmaceuticals Misses on EPS — Stock Down 3.69%

Ligand Pharmaceuticals reported a loss per share that was worse than expected, which contributed to a decline in its stock price by 3.69%. The lack of revenue figures and guidance adds to investor uncertainty. Overall, the company appears to be facing challenges that may impact its future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.05	N/A	-600.00%

Management

Management commentary

Tone: Defensive

Management expressed concerns about the ongoing market conditions affecting performance. They did not offer any forward guidance, indicating uncertainty.

Management did not provide specific guidance for future performance.

The company acknowledged challenges in the current market environment.

Ligand Pharmaceuticals Misses on EPS — Stock Down 3.69%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Misses on EPS — Stock Down 3.69%

Key numbers

Management commentary